Planmed shows Nuance mammography system with tomosynthesis capability
Planmed, which markets a variety of advanced mammography products, is showing its Nuance full-field digital mammography system during RSNA 2004. A work-in-progress, the Nuance is being displayed with a tomosynthesis capability.
Planmed, which markets a variety of advanced mammography products, is showing its Nuance full-field digital mammography system during RSNA 2004. A work-in-progress, the Nuance is being displayed with a tomosynthesis capability.
The system will offer clinicians a choice of two detector sizes utilizing direct digital capture amorphous selenium technology. Planmed bills it as enabling effortless image acquisition.
A one-piece magnification tower provides multiple imaging possibilities at 1.6x, 1.8x, and 2x. Precise needle guidance for stereotactic breast biopsy is accomplished with the optional DigiGuide system. Nuance also provides comprehensive DICOM compatibility for fast communication via hospital network.
On the analog side, Planmed is introducing the Nuance Classic with 48-sensor Flex-AEC anatomically adaptable exposure system. Flex-AEC reduces retakes while optimizing image quality, said Vesa Mattila, vice president of Planmed.
"The Nuance Classic provides a bridge to full-field digital technology," Mattila said. "Customers looking to a digital future will have a system that is truly field-upgradable."
The Nuance Classic will be available in January 2005.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
